ALSO NOTED: LAB Research gains financing; BMS, AstraZeneca, Wyeth report earnings; and much more...

> Stem Cell Sciences says a new pact with the Myelin Repair Foundation will provide it with a stable supply of uniform human brain cells for their research program on multiple sclerosis. Report

> Canada's LAB Research--a non-clinical contract research organization--has raised $21.1 million in fresh financing for its expansion plans. Release

> A handful of drug makers released their earnings, and it's a mixed bag: some up, some down, some hit by one-time charges. Here's a roundup. Report

> PsychoGenics has inked a new drug discovery pact with Eli Lilly covering the evaluation of neuropsychiatric drug candidates. Report

> Chutes & Ladders: Genelabs Technologies CEO James Smith has resigned. The company chairman and CFO will run the company until a new CEO is hired on. Report

> The FDA has granted priority review status to Schering-Plough's Peginterferon Alfa-2b, an adjuvant treatment for Stage III melanoma, a rare skin cancer. Release

> If remorse is proportional to the amount you're willing to pay to absolve it, then Eli Lilly must be feeling pretty guilty about Zyprexa. Report

> Can we trust a Chinese manufacturer that not only sold contaminated cancer drugs but tried to cover up the fact? Apparently, the FDA thinks so. Report

> Good news, needle-phobes. South Korean researchers have successfully tested a new approach to delivering vaccines, applying it under the tongue rather than through a needle. Report

And Finally... See that other blue-eyed person at the next table? Go say hi, because genetics proves that you're related to a common ancestor. Release

Suggested Articles

Dania Rabah, Ph.D., has become the new chief scientific officer at startup Rheos Medicines, coming off a stint at Biogen.

Peter Doshi has penned an opinion piece in the BMJ pointing out that current COVID-19 vaccine tests are not set up to save lives.

You may have heard of T cells before, but Aleks Radovic-Moreno, Be Biopharma’s co-founder, is betting on B cells as the future of cell therapies.